DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study

BACKGROUND: Vandetanib is a once-daily oral inhibitor of VEGFR, EGFR and RET signaling pathways. In patients with advanced colorectal cancer and liver metastases, the effect of vandetanib on tumor vasculature was assessed using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Mross, Klaus, Fasol, Ulrike, Frost, Annette, Benkelmann, Robin, Kuhlmann, Jan, Büchert, Martin, Unger, Clemens, Blum, Hubert, Hennig, Jürgen, Milenkova, Tsveta P, Tessier, Jean, Krebs, Annetta D, Ryan, Anderson J, Fischer, Richard
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2776237/
https://www.ncbi.nlm.nih.gov/pubmed/19946413
http://dx.doi.org/10.1186/2040-2384-1-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2776237/
https://www.ncbi.nlm.nih.gov/pubmed/19946413
http://dx.doi.org/10.1186/2040-2384-1-5

Ejemplares similares